Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
BTS beats; CI cardiac Index; CTD connective tissue disorder; CTEPH chronic thromboembolic pulmonary hypertension; DBP diastolic blood pressure; FC functional class; Ht hematocrit; HR heart rate; MPAP mean pulmonary artery pressure; PAWP pulmonary artery wedge pressure; PDE phosphodiesterase; PVR pulmonary vascular resistance; RAP right atrial pressure; SBP systolic blood pressure; Vit D vitamin D Characteristics of the left ventricular failure and healthy subjects groupsPH (n = 53)LVF (n = 42)HS (n = 31)Age (years)40.8 ± 16.558.6 ± 10 *40.5 ± 17Females (%)73.628.9 *74.2BMI (kg/m2)26.2 ± 530.9 ± 6 *25.2 ± 4FC (%)I: II71.286.7: III: IV28.813.3: VitD (mg/dL)19.25 ± 10.1 *25.68 ± 1228.8 ± 12Ht (%)43.9 ± 8.940.9 ± 7.540.6 ± 5.3Urea (mg/mL)34.49 ± 12.145.63 ± 16.333.6 ± 9.2 **Creatinine (mg/%)0.96 ± 0.91.04 ± 0.60.75 ± 0.3Sodium (mEq/Lt)140.4 ± 2.6137.7 ± 6.2140 ± 2.9Total bilirubin (mg/dL)1.14 ± 10.76 ± 0.80.57 ± 0.2 #LVEF (%)61.9 ± 734.3 ± 10 *65.4 ± 8LVDD (mm)43.5 ± 665.6 ± 10 *48.3 ± 23LA (mm)35.6 ± 846.84 ± 15 *39.7 ± 7SPAP (mmHg)81.55 ± 3 *43.91 ± 2331.84 ± 15 ***p < 0.05 vs. rest of groups; **p < 0.05 vs LVF; #p < 0.05 vs PH
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This cross-sectional study included three groups of patients: A) Patients with PH (consecutively recruited from the Pulmonary Hypertension program, Juan A.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Vitamin D deficiency among patients with pulmonary hypertension
Cross-sectional study · BMC Pulmonary Medicine · 2019
Original publication title
Vitamin D deficiency among patients with pulmonary hypertension
© The Author(s). 2019
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
There is little information about vitamin D (Vit D) deficiency in patients with pulmonary hypertension (PH). The objective of this study was: 1) compare Vit D levels between patients with PH, left ventricular failure (LVF) and healthy subjects (HS); 2) correlate, in patients with PH, Vit D levels with prognosis-related variables, such as the 6-min walk test (6MWT).
Source: BackgroundAbstract: What methods does the paper describe?
Vitamin D levels were measured in a cross-sectional study in 126 patients from one of three groups: patients with PH (n = 53), patients with LVF (n = 42) and healthy subjects (n = 31). In all groups, 8-h fasting blood samples were obtained in the morning. In the PH and the LVF group, functional class (WHO criteria), metres covered in the 6MWT and echocardiographic parameters were analysed. In the PH group, plasma N terminal pro B type natriuretic peptide (NT-proBNP) level was analysed and a complete haemodynamic evaluation by right heart catheterisation was made.
Source: MethodsAbstract: Results
Mean Vit D levels were lower in PH than in both other groups (ng/ml, mean ± SD): PH 19.25 ± 10, LVF 25.68 ± 12, HS 28.8 ± 12 (PH vs LVF p = 0.017, PH vs HS p = 0.001 and HS vs LVF p = 0.46). Vit D deficiency prevalence was higher in PH as compared to the other groups (PH 53.8%, LVF 45.2%, HS 25%, p = 0.01). Patients with PH in functional class (FC; WHO criteria) III: IV had higher Vit D deficiency prevalence than those in FC I: II (86.7% vs 40.5%, p = 0.003).
There was a significant linear correlation between the 6MWT and Vit D levels in PH (p < 0.01), but not in LVF (p = 0.69).
Source: ResultsAbstract: Conclusions
Vit D levels were lower in patients with PH as compared to patients with LVF and HS and correlated directly with 6-min walk distance.
Source: ConclusionsAuthors’ abstract
Background
There is little information about vitamin D (Vit D) deficiency in patients with pulmonary hypertension (PH). The objective of this study was: 1) compare Vit D levels between patients with PH, left ventricular failure (LVF) and healthy subjects (HS); 2) correlate, in patients with PH, Vit D levels with prognosis-related variables, such as the 6-min walk test (6MWT).
Methods
Vitamin D levels were measured in a cross-sectional study in 126 patients from one of three groups: patients with PH (n = 53), patients with LVF (n = 42) and healthy subjects (n = 31). In all groups, 8-h fasting blood samples were obtained in the morning. In the PH and the LVF group, functional class (WHO criteria), metres covered in the 6MWT and echocardiographic parameters were analysed. In the PH group, plasma N terminal pro B type natriuretic peptide (NT-proBNP) level was analysed and a complete haemodynamic evaluation by right heart catheterisation was made.
Results
Mean Vit D levels were lower in PH than in both other groups (ng/ml, mean ± SD): PH 19.25 ± 10, LVF 25.68 ± 12, HS 28.8 ± 12 (PH vs LVF p = 0.017, PH vs HS p = 0.001 and HS vs LVF p = 0.46). Vit D deficiency prevalence was higher in PH as compared to the other groups (PH 53.8%, LVF 45.2%, HS 25%, p = 0.01). Patients with PH in functional class (FC; WHO criteria) III: IV had higher Vit D deficiency prevalence than those in FC I: II (86.7% vs 40.5%, p = 0.003).
There was a significant linear correlation between the 6MWT and Vit D levels in PH (p < 0.01), but not in LVF (p = 0.69).
Conclusions
Vit D levels were lower in patients with PH as compared to patients with LVF and HS and correlated directly with 6-min walk distance.
Publication and source details
Original title: Vitamin D deficiency among patients with pulmonary hypertension
Andrés N. Atamañuk; Diego F. Litewka; Sergio J. Baratta; Ignacio M. Seropian; Graciela Perez Prados; Miguel O. Payaslian; Juan P. Ortiz Fragola; Pilar Escribano Subias
BMC Pulmonary Medicine · 2019
© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Actelion Pharmaceuticals LtdRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:42:59.367822+00:00
DOI: 10.1186/s12890-019-1011-7 · PMC6925472